title: Comparison of PLA microparticles and alum as adjuvants for H5N1 influenza split vaccine: adjuvanticity evaluation and preliminary action mode analysis.
abstract: OBJECTIVE
  To compare the adjuvanticity of polymeric particles (new-generation adjuvant) and alum (the traditional and FDA-approved adjuvant) for H5N1 influenza split vaccine, and to investigate respective action mode.
  
  
  METHODS
  Vaccine formulations were prepared by incubating lyophilized poly(lactic acid) (PLA) microparticles or alum within antigen solution. Antigen-specific immune responses in mice were evaluated using ELISA, ELISpot, and flow cytometry assay. Adjuvants' action modes were investigated by determining antigen persistence at injection sites, local inflammation response, antigen transport into draining lymph node, and activation of DCs in secondary lymphoid organs (SLOs).
  
  
  RESULTS
  Alum promoted antigen-specific humoral immune response. PLA microparticles augmented both humoral immune response and cell-mediated-immunity which might enhance cross-protection of influenza vaccine. With regard to action mode, alum adjuvant functions by improving antigen persistence at injection sites, inducing severe local inflammation, slightly improving antigen transport into draining lymph nodes, and improving the expression of MHC II on DCs in SLOs. PLA microparticles function by slightly improving antigen transport into draining lymph nodes, and promoting the expression of both MHC molecules and co-stimulatory molecules on DCs in SLOs.
  
  
  CONCLUSIONS
  Considering the adjuvanticity and side effects (local inflammation) of both adjuvants, we conclude that PLA microparticles are promising alternative adjuvant for H5N1 influenza split vaccine.
authors.affiliation: National Key Laboratory of Biochemical Engineering PLA Key Laboratory of Biopharmaceutical Production & Formulation Engineering, Institute of Process Engineering Chinese Academy of Sciences, Bei-Er-Jie No.1, Zhong-Guan-Cun, Haidian District, Beijing, 100190, People's Republic of China.
authors.forename: Weifeng
authors.initials: W
authors.lastname: Zhang
authors.forename: Lianyan
authors.initials: L
authors.lastname: Wang
authors.forename: Yuan
authors.initials: Y
authors.lastname: Liu
authors.forename: Xiaoming
authors.initials: X
authors.lastname: Chen
authors.forename: Jiahui
authors.initials: J
authors.lastname: Li
authors.forename: Tingyuan
authors.initials: T
authors.lastname: Yang
authors.forename: Wenqi
authors.initials: W
authors.lastname: An
authors.forename: Xiaowei
authors.initials: X
authors.lastname: Ma
authors.forename: Ruowen
authors.initials: R
authors.lastname: Pan
authors.forename: Guanghui
authors.initials: G
authors.lastname: Ma
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000534:Alum Compounds / Q000008:administration & dosage; D000818:Animals; D005260:Female; D006801:Humans; D056724:Immunity, Humoral / Q000187:drug effects / Q000276:immunology; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D019344:Lactic Acid / Q000008:administration & dosage / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008863:Microspheres; D011091:Polyesters; D011108:Polymers / Q000008:administration & dosage; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000534:Alum Compounds; D007252:Influenza Vaccines; D011091:Polyesters; D011108:Polymers; D019344:Lactic Acid; C041524:aluminum sulfate; C033616:poly(lactide)